Skip to main content

Table 1 Patient characteristics

From: Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

  SS
(n = 58)
HS
(n = 59)
ES
(n = 55)
Age, years 58.5 ± 15.0 58.1 ± 15.9 60.1 ± 14.4
Female, % 63.8 64.4 70.9
Body weight, kg 55.9 ± 11.8 56.8 ± 10.9 54.5 ± 9.9
Diagnosis
 RA, % 8.6 6.8 7.3
 SLE, % 10.3 11.9 10.9
 PM/DM, % 19.0 37.3 29.1
 Vasculitis syndrome, % 44.8 25.4 30.9
 Othersa, % 17.2 18.6 21.8
Disease duration, months (IQR) 2 (1–5) 3 (2–7) 4 (2–9)
Comorbidities, % 72.4 79.7 78.2
 ILD, % 38.0 44.1 43.6
 Other lung comorbiditiesb, % 12.1 8.5 5.5
 Hypertension, % 13.8 18.6 14.5
 Diabetes, % 6.9 5.1 14.5
 CVDc, % 3.4 5.1 5.5
 CKD, % 1.7 0 0
 Malignancies, % 6.9 11.9 9.1
 Others, % 41.4 42.3 36.4
Baseline laboratory data
 WBC, /μL (NR, 3300‒8600) 10401 ± 5359 9901 ± 4767 9743 ± 5177
 Lymphocyte, /μL 1766 ± 1106 1933 ± 1244 1656 ± 877
 IgG, mg/dL (NR, 861‒1747) 1676 ± 677 1668 ± 679 2006 ± 1945
Treatment before enrollmentd
 CS, % 15.5 13.3 14.5
 Dosage of CSe, mg/day (IQR) 13.8 (5–15) 8.8 (5–10.6) 6.8 (5–8.125)
 ISf, % 1.7 3.2 7.3
 Biologics, % 1.7 0 0
Dosage of concomitant CS
 At baseline, mg/kg/day (IQR) 0.97 (0.89–1.01) 0.97 (0.81–1.02) 0.94 (0.75–1.05)
 At week 24, mg/day (IQR) 12.5 (10–14.25) 11 (9–15) 10 (9–12.5)
Other immunosuppressive treatment between weeks 0 and 12
 IV pulsed mPSL, % 20.6 32.2 20
 IS, % 70.6 67.8 81.8
 Biologics, % 1.7 3.4 1.8
Other immunosuppressive treatment between weeks 12 and 24
 IV pulsed mPSL, % 1.7 3.4 0
 IS, % 65.5 72.9 78.2
 Biologics, % 1.7 1.7 3.6
  1. Values that conform to the normal distribution are expressed as the mean ± SD. Values that do not conform to the normal distribution are expressed as the median (interquartile range). aOthers include systemic sclerosis, mixed connective tissue diseases, Sjogren’s syndrome, adult-onset Still’s disease, relapsing polychondritis, IgG4-related disease, and antiphospholipid syndrome. bOther lung comorbidities include chronic obstructive lung disease, bronchiectasis, bronchial asthma, pulmonary hypertension, and old tuberculosis. cCardiovascular diseases include cerebral infarction, cerebral hemorrhage, myocardial infarction, and angina pectoris. dTreatment between 84 days and 1 day before starting or intensifying immunosuppressive treatment. ePrednisolone equivalent dose. fImmunosuppressive drugs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, mizoribine, and mycophenolate mofetil, and tacrolimus. SS the single-strength dosage group, HS the half-strength dosage group, ES the escalation dosage group, RA rheumatoid arthritis, SLE systemic lupus erythematosus, PM polymyositis, DM dermatomyositis, IQR interquartile range, ILD interstitial lung disease, CVD cardiovascular disease, CKD chronic kidney disease, WBC white blood cell, NR normal range, CS corticosteroids, mPSL methylpredonisolone, IS immunosuppressive drugs, IV intravenous